Zimycan “Not Approvable” Letter Could Mean One-Year Approval Delay
This article was originally published in Pharmaceutical Approvals Monthly
Barrier Therapeutics believes it may have to conduct a second absorption study for its antifungal ointment Zimycan following receipt of a "not approvable" letter May 24
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class